SCHEMBL6446517

SCHEMBL6446517

N#Cc1c(-c2ccco2)nc(N)nc1N1CCOCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.67
ALDH1A1 P00352 7/20 0.67
HPGD P15428 7/20 0.67
GAA P10253 2/20 0.67
HIF1A Q16665 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
ADORA2A P29274 5/20 0.57
ADORA2B P29275 3/20 0.57
ADORA1 P30542 3/20 0.57
ERAP1 Q9NZ08 1/20 0.53
HSD17B10 Q99714 4/20 0.50
MAPT P10636 4/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47
ATM Q13315 2/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
IKBKB O14920 1/20 0.45
KHK P50053 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036770 0.89 ADORA2A (0.58) KDM4EALDH1A1HPGDGAAHIF1A
SCHEMBL6445134 0.88 ADORA2A (0.61) KDM4EALDH1A1HPGDGAAHIF1A
SCHEMBL6448539 0.87 ADORA2A (0.56) KDM4EALDH1A1HPGDGAAHIF1A
SCHEMBL6447580 0.81 KDM4E (0.75) KDM4EALDH1A1HPGDADORA2AADORA2B
SCHEMBL5131931 0.81 ADORA2A (0.55) KDM4EALDH1A1HPGDGAAHIF1A
SCHEMBL6255135 0.80 ALDH1A1 (1.00) KDM4EALDH1A1HPGDGAAHIF1A
SCHEMBL6446501 0.80 HPGD (0.62) KDM4EALDH1A1HPGDGAAHIF1A
SCHEMBL6441656 0.76 ADORA1 (0.49) KDM4EALDH1A1HPGDGAAHIF1A
SCHEMBL6444222 0.76 ALDH1A1 (0.63) KDM4EALDH1A1HPGDGAAHIF1A
SCHEMBL6441202 0.76 ADORA2A (0.72) KDM4EALDH1A1HPGDGAAADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 KDM4E 3250/4885ALDH1A1 534/4885HPGD 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.